To investigate the efficacy of dapagliflozin as an adjunctive therapy in early-stage diabetic nephropathy(DN) and its impact on blood glucose, insulin resistance(IR), and stress response.
Patients with early-stage DN admitted to endocrinology department of Linquan county people's hospital from February 2022 to February 2025 were selected as study subjects and randomly divided into the observation group and the control group, with 60 cases in each group. The control group was treated with metformin combined with valsartan, while the observation group additionally received dapagliflozin. The treatment course lasted 3 months. The efficacy, blood glucose levels, IR, stress response, renal function, and safety were compared between the two groups after 1 month and 3 months of treatment.
After 1 month of treatment, there were no significant differences in the levels of 24-hour urine protein(24hUP), serum creatinine(Scr), and estimated glomerular filtration rate(eGFR) between the two groups(P>0.05). After 3 months of treatment, the total effective rate of the observation group was higher than that of the control group(90.00% vs. 75.00%, P<0.05). The eGFR levels of both groups increased compared with those before treatment(P<0.05), and the observation group was higher than that in the control group(P<0.05). Both 24hUP and Scr levels decreased compared with those before treatment(P<0.05), and the observation group was lower than that in the control group(P<0.05). Fasting blood glucose, glycated hemoglobin, 2-hour postprandial blood glucose, and IR index levels assessed by homeostasis model in the observation group were lower than those in the control group(P<0.05).Tumor necrosis factor-α and interleukin-6 in both groups were decreased than those before treatment(P<0.05), and the observation group was lower than the control group(P<0.05). There was no significant difference in complication incidence between the two groups(P>0.05).
Dapagliflozin demonstrates significant efficacy as an adjunctive therapy for early-stage DN, effectively improving blood glucose levels, alleviating IR, and reducing inflammatory responses.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |